Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (Nasdaq: AUTL), a commercial-stage biopharmaceutical company focused on programmed T cell therapies, has announced its participation in two upcoming investor conferences in Miami, FL.
The company will attend the Jefferies Biotech on the Beach Summit on March 11, 2025, where management will host investor meetings. Additionally, CEO Dr. Christian Itin will deliver a fireside chat presentation at the Leerink Global Biopharma Conference on March 12, 2025, at 8:40am EDT / 12:40pm GMT.
A webcast of the fireside chat will be accessible through the company's website's 'Events' page, with a replay available for 90 days post-presentation.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase commerciale focalizzata sulle terapie con cellule T programmate, ha annunciato la sua partecipazione a due prossime conferenze per investitori a Miami, FL.
L'azienda parteciperà al Jefferies Biotech on the Beach Summit l'11 marzo 2025, dove la direzione ospiterà incontri con gli investitori. Inoltre, il CEO Dr. Christian Itin presenterà una chiacchierata informale alla Leerink Global Biopharma Conference il 12 marzo 2025, alle 8:40 EDT / 12:40 GMT.
Una trasmissione in diretta della chiacchierata informale sarà accessibile attraverso la pagina 'Eventi' del sito web dell'azienda, con una registrazione disponibile per 90 giorni dopo la presentazione.
Autolus Therapeutics (Nasdaq: AUTL), una empresa biofarmacéutica en etapa comercial centrada en terapias con células T programadas, ha anunciado su participación en dos próximas conferencias para inversores en Miami, FL.
La empresa asistirá al Jefferies Biotech on the Beach Summit el 11 de marzo de 2025, donde la dirección llevará a cabo reuniones con inversores. Además, el CEO Dr. Christian Itin ofrecerá una charla informal en la Leerink Global Biopharma Conference el 12 de marzo de 2025, a las 8:40 a.m. EDT / 12:40 p.m. GMT.
Una transmisión en vivo de la charla informal estará disponible a través de la página de 'Eventos' del sitio web de la empresa, con una repetición disponible durante 90 días después de la presentación.
Autolus Therapeutics (Nasdaq: AUTL)는 프로그래밍된 T 세포 치료에 중점을 둔 상업 단계의 생명공학 회사로, 플로리다주 마이애미에서 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 11일 Jefferies Biotech on the Beach Summit에 참석하며, 경영진이 투자자 회의를 주최할 예정입니다. 또한, CEO인 Dr. Christian Itin은 2025년 3월 12일 오전 8시 40분 EDT / 오후 12시 40분 GMT에 Leerink Global Biopharma Conference에서 화상 대담을 진행할 것입니다.
화상 대담의 웹캐스트는 회사 웹사이트의 '이벤트' 페이지를 통해 접근할 수 있으며, 발표 후 90일 동안 재생할 수 있습니다.
Autolus Therapeutics (Nasdaq: AUTL), une entreprise biopharmaceutique en phase commerciale axée sur les thérapies par cellules T programmées, a annoncé sa participation à deux prochaines conférences pour investisseurs à Miami, FL.
L'entreprise assistera au Jefferies Biotech on the Beach Summit le 11 mars 2025, où la direction organisera des réunions avec les investisseurs. De plus, le PDG Dr. Christian Itin présentera une discussion informelle lors de la Leerink Global Biopharma Conference le 12 mars 2025, à 8h40 EDT / 12h40 GMT.
Un webinaire de la discussion informelle sera accessible via la page 'Événements' du site Web de l'entreprise, avec un replay disponible pendant 90 jours après la présentation.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf programmierte T-Zell-Therapien konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen in Miami, FL, bekannt gegeben.
Das Unternehmen wird am Jefferies Biotech on the Beach Summit am 11. März 2025 teilnehmen, wo das Management Investorenmeetings veranstalten wird. Darüber hinaus wird CEO Dr. Christian Itin am 12. März 2025 um 8:40 Uhr EDT / 12:40 Uhr GMT eine informelle Gesprächsrunde auf der Leerink Global Biopharma Conference halten.
Ein Webcast der informellen Gesprächsrunde wird über die 'Events'-Seite der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Präsentation verfügbar ist.
- None.
- None.
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.
Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 11, 2025
Location: Miami, FL
Leerink Global Biopharma Conference
Fireside Chat Presentation
Date and time: March 12, 2025; 8:40am EDT / 12:40pm GMT
Location: Miami, FL
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
When is Autolus Therapeutics (AUTL) presenting at the Leerink Global Biopharma Conference 2025?
Which investor conferences will Autolus Therapeutics (AUTL) attend in March 2025?
How long will the AUTL Leerink Conference webcast be available for replay?
Who will represent Autolus Therapeutics (AUTL) at the Leerink Global Biopharma Conference?
